Peregrine Pharmaceuticals (PPHM) : During the past 4 weeks, traders have been relatively bearish on Peregrine Pharmaceuticals (PPHM), hence the stock is down -12.59% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.71% relative to the S&P 500. The 4-week change in the price of the stock is -8.77% and the stock has fallen -1.26% in the past 1 week. The stock has recorded a 20-day Moving Average of 2.18% and the 50-Day Moving Average is 4.32%.
Peregrine Pharmaceuticals (NASDAQ:PPHM): The stock opened at $0.41 on Friday but the bulls could not build on the opening and the stock topped out at $0.41 for the day. The stock traded down to $0.39 during the day, due to lack of any buying support eventually closed down at $0.39 with a loss of -11.27% for the day. The stock had closed at $0.43 on the previous day. The total traded volume was 1,727,962 shares.
The company Insiders own 5.06% of Peregrine Pharmaceuticals shares according to the proxy statements. Institutional Investors own 16.98% of Peregrine Pharmaceuticals shares.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Companys therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.